Locoregional treatment of primary tumor in synchronous metastatic head and neck squamous cell carcinomas

被引:0
|
作者
Tang, Eliane [1 ]
Schwartz, Boris [2 ]
Limkin, Elaine [1 ]
Even, Caroline [3 ]
Blanchard, Pierre [1 ]
Haddy, Nadia [2 ]
Gorphe, Philippe [4 ]
Ferrand, Francois-Regis [3 ]
Tao, Yungan [1 ]
Nguyen, Thanh-Van-France [1 ]
机构
[1] Gustave Roussy, Dept Radiat Oncol, Villejuif, France
[2] Gustave Roussy, Dept Radiat Epidemiol, Unite 1018, INSERM, Villejuif, France
[3] Gustave Roussy, Dept Head & Neck Oncol, Villejuif, France
[4] Gustave Roussy, Dept Head & Neck Surg, Villejuif, France
关键词
Head and neck; squamous cell carcinoma; metastases; locoregional treatment; radiation therapy; OPEN-LABEL; CHEMOTHERAPY; SURVIVAL; CETUXIMAB; IMPACT; MULTICENTER; RECURRENT; PLATINUM; THERAPY; CANCER;
D O I
10.1080/0284186X.2023.2209266
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposePatients with synchronous metastatic head and neck squamous cell carcinomas (mHNSCC) are at risk of locoregional progression associated with significant morbidity and mortality. The aim of this study is to assess whether the addition of aggressive locoregional treatment to systemic therapy could be associated with an improved overall survival (OS) compared to systemic therapy alone in upfront mHNSCC patients.Material and methodsThis retrospective study included patients presenting with previously untreated mHNSCC who underwent first-line systemic therapy at a single institution between 1998 and 2018. Locoregional treatment was defined as either exclusive locoregional radiotherapy (RT) or surgery with or without adjuvant RT.ResultsOne hundred forty-eight patients were included. Eighty patients were treated with systemic therapy alone and 68 patients were treated with a combination of locoregional treatment and systemic therapy. Median overall survival (OS) was 13 months [10.7-15] and median progression free survival (PFS) was 7.7 month [6.5-8.9]. The addition of a locoregional treatment to systemic therapy compared to systemic therapy alone was associated with improved survival (1-year OS, 65.8% vs. 41.1%, p < .001, and 1-year PFS, 42.5% vs. 18.5%, p < .001). Moreover, RT dose equal to 70 Gy was associated with even longer OS compared to a RT dose below 70 Gy and to no locoregional treatment (23.4 vs. 12.7 vs 7.5 months respectively). In a subgroup analysis on 75 patients presenting with a responding or stable metastatic disease after first-line systemic therapy, oropharyngeal primary tumor site and the addition of a locoregional treatment, especially a high radiation dose of 70 Gy, were evidenced as independent prognostic factors for improved OS.ConclusionThe addition of a high-dose RT locoregional treatment to systemic therapy is associated with prolonged OS in patients with synchronous mHNSCC and should be discussed for patients who respond to or have a stable disease after first-line systemic therapy.
引用
收藏
页码:465 / 472
页数:8
相关论文
共 50 条
  • [31] Metastatic squamous cell carcinomas of the head and neck to lung: Immunohistochemical and molecular analysis
    Finkelstein, SD
    Pereira, TC
    Liu, YL
    Singh, HK
    Silverman, JF
    LABORATORY INVESTIGATION, 2006, 86 : 207A - 207A
  • [32] Reappraisal of metastatic lymph node topography in head and neck squamous cell carcinomas
    Tao, Lei
    Lefevre, Marine
    Callard, Patrice
    Perie, Sophie
    Bernaudin, Jean-Francois
    St Guily, Jean Lacau
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2006, 135 (03) : 445 - 450
  • [33] COMMON CLONAL ORIGIN OF SYNCHRONOUS PRIMARY HEAD AND NECK SQUAMOUS-CELL CARCINOMAS - ANALYSIS BY TUMOR KARYOTYPES AND FLUORESCENCE IN-SITU HYBRIDIZATION
    WORSHAM, MJ
    WOLMAN, SR
    CAREY, TE
    ZARBO, RJ
    BENNINGER, MS
    VANDYKE, DL
    HUMAN PATHOLOGY, 1995, 26 (03) : 251 - 261
  • [34] CELLULAR RADIOSENSITIVITY OF PRIMARY HEAD AND NECK SQUAMOUS-CELL CARCINOMAS AND LOCAL TUMOR-CONTROL
    BROCK, WA
    BAKER, FL
    WIKE, JL
    SIVON, SL
    PETERS, LJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (06): : 1283 - 1286
  • [35] A REVIEW OF EPIDEMIOLOGY, PROGNOSIS, AND TREATMENT OPTIONS FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCC)
    Blieden, M.
    Muszbek, N.
    Chaudhary, M. A.
    Zhang, Y.
    VALUE IN HEALTH, 2017, 20 (05) : A94 - A94
  • [36] Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
    Saada-Bouzid, Esma
    Peyrade, Frederic
    Guigay, Joel
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (03) : 196 - 203
  • [37] NEOADJUVANT CHEMOTHERAPY IN MULTIPLE SYNCHRONOUS HEAD AND NECK AND ESOPHAGUS SQUAMOUS-CELL CARCINOMAS
    GUILLOT, T
    SPIELMANN, M
    KAC, J
    LUBOINSKI, B
    TELLEZBERNAL, E
    MUNCK, JN
    BACHOUCHI, M
    ARMAND, JP
    CVITKOVIC, E
    LARYNGOSCOPE, 1992, 102 (03): : 311 - 319
  • [38] Cetuximab in squamous cell head and neck carcinomas
    Gebbia, V.
    Giuliani, F.
    Valori, V. M.
    Agueli, R.
    Coiucci, G.
    Maiello, E.
    ANNALS OF ONCOLOGY, 2007, 18 : 5 - 7
  • [39] Basaloid squamous cell carcinomas of the head and neck
    Thariat, J.
    Badoual, C.
    Faure, C.
    de Mones, E.
    Butori, C.
    Santini, J.
    Poissonnet, G.
    Maingon, P.
    Faivre, S.
    Klijanienko, J.
    Saint-Guily, J. Lacau
    Righini, C. A.
    BULLETIN DU CANCER, 2009, 96 (10) : 989 - 1004
  • [40] Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas
    Hsu, Cheng-Ming
    Yang, Ming-Yu
    Tsai, Ming-Shao
    Chang, Geng-He
    Yang, Yao-Hsu
    Tsai, Yao-Te
    Wu, Ching-Yuan
    Chang, Shun-Fu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)